Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

tion with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10- day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory fai
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... World Drug Safety Congress in Boston, MA, ePharmaSolutions announced ... system to support the most recent national and local ... advanced distribution and tracking capabilities. The distribution ... and time consuming process for global biopharmaceutical companies who ...
... The Female Health Company (NASDAQ-CM: FHCO), today announced that its ... $0.05 per share.  The dividend is payable May 10, 2011 ... In January, 2010, the Company announced the initiation of ... dividends since the program,s inception. "The Company,s Board ...
Cached Medicine Technology:ePharmaSolutions Launches Major Release of Its Global Safety Letter Distribution and Tracking Application in More Than 90 Countries 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 3
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most ... outfits, has released its new range of elegant ... are available at discounted prices. Worldwide clients can enjoy ... In the company’s online shop, there are plenty of ... made with great materials. MyDressCity.com’s hot items are prom ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... A decreased ability to identify odors might indicate ... while examinations of the eye could indicate the ... in the brain, according to the results of ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... ability to identify odors was significantly associated with ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... Lipitor bellwether trial has been scheduled in July of ... The Lipitor lawsuits are in the discovery process ... Judge Richard M. Gergel is presiding over the multidistrict ... were filed on behalf of individuals who allege that ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at ... for her seven children,all of whom live with asthma. ... new television show revealing Nytera,s story and others,behind the ... "Union Time" and it,s the only national labor-produced TV ...
... Mass., USA (February 7, 2008) After just seven months ... been named the 2007 Best New Journal - Science, Technology ... of the Association of American Publishers (AAP). , This honor, ... for Excellence, comes less than a year after Cell Stem ...
... Transcept Pharmaceuticals,Inc. today announced that Glenn A. ... the 10th Annual BIO CEO & Investor Conference ... Tuesday, February 12, 2008 at,10:15 AM Eastern Time., ... is a specialty pharmaceutical company,deriving significant new patient ...
... March Meeting of American Physical Society will take place March ... scientists are expected to be on hand. The principal ... materials, chemical and biological physics, fluids, polymers, and computation. , ... is both a great showcase for fundamental physics research and ...
... Owners and employees agree that the rising ... WASHINGTON, Feb. 7 Post-primary polling,shows small-business ... voting,segment equal to, and larger than, well-established ... The National Federation of Independent Business (NFIB), ...
... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
Cached Medicine News:Health News:Cell Stem Cell named 'Best New Journal' of 2007 2Health News:Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Health News:Physics breakthroughs on tap at New Orleans conference 2Health News:Small Business Turns Out on Super Tuesday 2Health News:Small Business Turns Out on Super Tuesday 3Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: